TrialTargeted oncology2023

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Albiruni R Abdul Razak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.